Abstract | AIM: METHODS: This randomized, double-blind, double-dummy, multicenter, controlled trial recruited 253 outpatients randomized to receive either brotizolam (n = 126) or estazolam (n = 127) for 14 days followed by 1 week of follow-up for rebound detection. Sleep Dysfunction Rating Scale (SDRS) and Clinical General Impression Scale were applied for efficacy evaluation. Safety evaluation was based on data regarding vital signs, physical examination, lab tests, ECG and collection of adverse events. RESULTS: Full Analyses Set (FAS) and Safety Set (SS) included data of 251 subjects, with 126 from brotizolam group and 125 from estazolam group. Per Protocol Set (PPS) analysis included data of 235 subjects, with 121 and 114 from each group. After 14 days of treatment, there was no difference with statistical significance between the two groups regarding SDRS total score change from baseline. FAS and PPS analysis showed that the brotizolam is non-inferior to estazolam in efficacy evaluation. There was also no difference with statistical significance regarding rebound rate between brotizolam and estazolam group in FAS. The rate of adverse event in two groups was with no statistically significant difference in SS. CONCLUSION:
|
Authors | Xiaolei Yan, Shuzhen Huang, Cui Ma, Yang Shen, Niufan Gu, Haibo Chen, Wenyuan Wu, Shunwei Li, Zhen Hong, Huafang Li |
Journal | International journal of psychiatry in clinical practice
(Int J Psychiatry Clin Pract)
Vol. 17
Issue 4
Pg. 239-43
(Oct 2013)
ISSN: 1471-1788 [Electronic] England |
PMID | 23025837
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Anxiety Agents
- Azepines
- Hypnotics and Sedatives
- Estazolam
- brotizolam
|
Topics |
- Adolescent
- Adult
- Aged
- Analysis of Variance
- Anti-Anxiety Agents
(therapeutic use)
- Azepines
(pharmacology, therapeutic use)
- China
- Double-Blind Method
- Estazolam
(therapeutic use)
- Female
- Humans
- Hypnotics and Sedatives
(pharmacology, therapeutic use)
- Male
- Middle Aged
- Outpatients
- Severity of Illness Index
- Sleep Initiation and Maintenance Disorders
(drug therapy)
- Treatment Outcome
- Young Adult
|